Titan Capital Backs xStep Neurotech for Rehabilitation

Neurotechnology innovator xStep has secured backing from Titan Capital, marking a significant step in its mission to broaden access to advanced neurorehabilitation. The investment, the specifics of which remain undisclosed, will accelerate the commercial rollout of xStep's non-invasive spinal neuromodulation platform, designed to aid individuals affected by conditions such as cerebral palsy, stroke, and multiple sclerosis.

Emerging from nearly two decades of foundational research at the University of California, Los Angeles (UCLA) led by neuroscientist Dr. Parag Gad, xStep translates complex scientific discoveries into practical therapeutic tools. The company's proprietary technology, developed in collaboration with SpineX Inc. (USA) and manufactured by VIVATRONIX Tech Pvt. Ltd. (India), utilizes targeted, non-surgical electrical stimulation applied through the skin. This approach aims to enhance motor function, balance, and sensory recovery, offering a more accessible alternative to traditional, often invasive, treatments.

The global burden of neurological disorders, a leading cause of long-term disability, underscores the critical need for scalable and affordable rehabilitation solutions. xStep's strategy directly addresses this gap, focusing on making its advanced therapies available to a wider patient population, particularly in emerging markets. The company's recent expansion includes the launch of xStep One, an integrated neurorehabilitation center in Bengaluru, which also features robotic gait training technology through a partnership with Trexo Robotics.

This funding injection is earmarked for several key growth areas: expanding commercial operations across India, scaling up manufacturing capabilities, generating robust clinical evidence, and navigating regulatory pathways both domestically and internationally. xStep has demonstrated significant progress over the past year, transitioning from a research-centric entity to a commercially viable enterprise with established relationships across the healthcare ecosystem.

Dr. Parag Gad, founder and CEO of xStep, emphasized the company's core philosophy: "This investment validates our long-term vision of putting advanced neurorehabilitation within reach of patients everywhere." He highlighted the critical role of Titan Capital, including Kunal Bahl, Rohit Bansal, and Manik Pasricha, in enabling the company to scale manufacturing, broaden clinical access, and build essential evidence. The company's approach, encapsulated by "Rewire. Retrain. Restore.," focuses on reactivating neural pathways and pairing neuromodulation with intensive therapy to improve patient independence and quality of life.

With over 1,000 individuals already benefiting from xStep's technology and ongoing clinical studies in more than 20 countries, the company is building a strong foundation of real-world evidence. This data is crucial for supporting wider clinical adoption and securing future regulatory approvals in diverse global markets. Titan Capital recognized xStep's blend of strong scientific grounding, patient-centric benefits, and a pragmatic commercial strategy, positioning it as a company poised to redefine neurological rehabilitation delivery worldwide.